KRISTINA DADA: Open Payments
NPI 1487830097 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,293 in 111 payments from 21 companies in 2025. Trend: 2023 $1,262 · 2024 $2,950 · 2025 $2,293
Food & beverage: $2,293
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 23 | $643 |
| Insmed, Inc. | 11 | $224 |
| Merck Sharp & Dohme LLC | 6 | $186 |
| GENZYME CORPORATION | 12 | $176 |
| Grifols USA, LLC | 9 | $166 |
| JAZZ PHARMACEUTICALS INC. | 8 | $153 |
| Regeneron Healthcare Solutions, Inc. | 7 | $108 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $99 |
| GlaxoSmithKline, LLC. | 5 | $90 |
| HARMONY BIOSCIENCES LLC | 3 | $66 |
Products named: FASENRA, DUPIXENT, Arikayce, Prolastin-C Liquid, WINREVAIR, XYWAV, NUCALA, WAKIX.
Industry payments across NE — which companies pay providers there.
